Kinase inhibitor: MEK. Inhibits SARS-CoV and MERS-CoV in cells. Laise et al. bioRxiv, May 17 2020, https://doi.org/10.1101/2020.05.12.091256; Zumla et al. Nat. Rev. Drug Discov. 15:327–347 2016, https://dx.doi.org/10.1038/nrd.2015.37.
Biochemicals & reagents
1) Sebolt-Leopold et al. (2004), The biological profile of PD0325901: A second generation analog of CI-1040 with improved pharmaceutical potential; Proc. Amer. Assoc. Cancer Res., 45 925 2) Ciuffreda et al. (2009), Growth-inhibitor and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations; Neoplasia, 11 720 3) Ai et al. (2016), Maintenance of Self-Renewal and Pluripotency in J1 Mouse Embryonic Stem Cells through Regulating Transcription Factor and MicroRNA Expression Induced by PD0325901; Stem Cells Int., 2016 1792573 4) Li et al. (2016), MEK inhibitor PD0325901 and vitamin C synergistically induce hypomethylation of mouse embryonic stem cells; Oncotarget, 7 39730 5) Li et al. (2009), Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors; Cell Stem Cell, 4 16
PD-325901 is a selective non-ATP competitive MEK inhibitor (IC50 = 0.33 nM) (1) which inhibits the growth and/or proliferation of a variety of cancer cells (2). This compound enhances self-renewal of embryonic stem cells (3) and in combination with vitamin C, synergistically induces hypomethylation of mouse embryonic stem cells (4). Also, in combination with CHIR-99021 and A83-01 it induces generation of ground state iPS cells from human and rat somatic cells (5).